S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

DexCom Stock Forecast, Price & News

+5.36 (+1.25%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
841,812 shs
Average Volume
987,168 shs
Market Capitalization
$42.18 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DexCom logo

About DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.93 billion
Cash Flow
$3.74 per share
Book Value
$19.02 per share


Net Income
$493.60 million
Pretax Margin




Free Float
Market Cap
$42.18 billion

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Social Links


Overall MarketRank

2.77 out of 5 stars

Medical Sector

47th out of 1,415 stocks

Surgical & Medical Instruments Industry

5th out of 130 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

DexCom (NASDAQ:DXCM) Frequently Asked Questions

Is DexCom a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom
or view top-rated stocks.

How has DexCom's stock been impacted by Coronavirus?

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DXCM shares have increased by 72.4% and is now trading at $435.23.
View which stocks have been most impacted by COVID-19

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for DexCom

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, February 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings results on Thursday, October, 28th. The medical device company reported $0.89 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.62 by $0.27. The medical device company had revenue of $650.20 million for the quarter, compared to analyst estimates of $617.07 million. DexCom had a trailing twelve-month return on equity of 14.65% and a net margin of 22.82%. DexCom's revenue for the quarter was up 29.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.94 earnings per share.
View DexCom's earnings history

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.43 billion-$2.45 billion, compared to the consensus revenue estimate of $2.40 billion.

What price target have analysts set for DXCM?

14 analysts have issued 1-year target prices for DexCom's shares. Their forecasts range from $438.00 to $715.00. On average, they expect DexCom's share price to reach $587.64 in the next twelve months. This suggests a possible upside of 35.0% from the stock's current price.
View analysts' price targets for DexCom
or view top-rated stocks among Wall Street analysts.

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Kevin Ronald Sayer, Chairman, President & Chief Executive Officer
  • Jereme M Sylvain, SVP-Finance, Chief Financial & Accounting Officer (LinkedIn Profile)
  • Andrew K. Balo, EVP-Clinical Affairs, Regulatory Strategy (LinkedIn Profile)
  • Jacob S. Leach, Chief Technology Officer & Executive VP
  • Shelly R. Selvaraj, Senior Vice President-Information Technology

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a number of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.22%), Royal London Asset Management Ltd. (0.03%), Gradient Investments LLC (0.03%), Scout Investments Inc. (0.02%), State of Alaska Department of Revenue (0.02%) and DNB Asset Management AS (0.02%). Company insiders that own DexCom stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends for DexCom

Which major investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Scout Investments Inc., Cutler Group LP, Crossmark Global Holdings Inc., IBM Retirement Fund, Royal London Asset Management Ltd., New Mexico Educational Retirement Board, and Carroll Financial Associates Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barry J Regan, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven Robert Pacelli, and Sumi Shrishrimal.
View insider buying and selling activity for DexCom
or view top insider-selling stocks.

Which major investors are buying DexCom stock?

DXCM stock was bought by a variety of institutional investors in the last quarter, including Gradient Investments LLC, NuWave Investment Management LLC, DNB Asset Management AS, State of Alaska Department of Revenue, Integrated Investment Consultants LLC, Gilman Hill Asset Management LLC, Louisiana State Employees Retirement System, and Strong Tower Advisory Services.
View insider buying and selling activity for DexCom
or or view top insider-buying stocks.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $435.23.

How much money does DexCom make?

DexCom has a market capitalization of $42.18 billion and generates $1.93 billion in revenue each year. The medical device company earns $493.60 million in net income (profit) each year or $5.23 on an earnings per share basis.

How many employees does DexCom have?

DexCom employs 6,400 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

When was DexCom founded?

DexCom was founded in 1999.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

Where are DexCom's headquarters?

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 200-0200, via email at [email protected], or via fax at 858-200-0201.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.